Lu‐Gang Yu

4.8k total citations
102 papers, 3.7k citations indexed

About

Lu‐Gang Yu is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Lu‐Gang Yu has authored 102 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Molecular Biology, 50 papers in Immunology and 17 papers in Oncology. Recurrent topics in Lu‐Gang Yu's work include Galectins and Cancer Biology (47 papers), Glycosylation and Glycoproteins Research (37 papers) and Signaling Pathways in Disease (13 papers). Lu‐Gang Yu is often cited by papers focused on Galectins and Cancer Biology (47 papers), Glycosylation and Glycoproteins Research (37 papers) and Signaling Pathways in Disease (13 papers). Lu‐Gang Yu collaborates with scholars based in United Kingdom, China and Netherlands. Lu‐Gang Yu's co-authors include Jonathan M. Rhodes, Anna U. Newlaczyl, Xiuli Guo, Qicheng Zhao, Hannah Barrow, J.D. Milton, John Hilkens, David G. Fernig, Barry J. Campbell and D. Mark Pritchard and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and PLoS ONE.

In The Last Decade

Lu‐Gang Yu

97 papers receiving 3.6k citations

Peers

Lu‐Gang Yu

IMMUN

ONCOL

RNMI

Paula A. Videira Portugal

Judith A. Fox United States

Rehan Ahmad United States

Sara Huerta‐Yépez Mexico

Kenji Ishitsuka Japan

Hisafumi Yamada‐Okabe Japan

Peter A. Cohen United States

Arjan A. van de Loosdrecht Netherlands

Pratima Nangia‐Makker United States

Kenneth D. Greis United States

Paula A. Videira Portugal

Lu‐Gang Yu

1.6k ×0.6

925 ×0.5

IMMUN

391 ×0.6

ONCOL

334 ×1.1

242 ×0.8

RNMI

Citations per year, relative to Lu‐Gang Yu Lu‐Gang Yu (= 1×) peers Paula A. Videira

Countries citing papers authored by Lu‐Gang Yu

Since Specialization

Citations

This map shows the geographic impact of Lu‐Gang Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu‐Gang Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu‐Gang Yu more than expected).

Fields of papers citing papers by Lu‐Gang Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu‐Gang Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu‐Gang Yu. The network helps show where Lu‐Gang Yu may publish in the future.

Co-authorship network of co-authors of Lu‐Gang Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Lu‐Gang Yu. A scholar is included among the top collaborators of Lu‐Gang Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu‐Gang Yu. Lu‐Gang Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Xiaoxin, et al.. (2025). Targeting galectin-3 in cancer by novel and unique inhibitors of non-carbohydrate origin. Molecular Medicine. 31(1). 299–299.

Li, Lingli, Dezhi Li, Shenghua Zhou, et al.. (2024). Unveiling age-friendliness in smart cities: A heterogeneity analysis perspective based on the IAHP-CRITIC-IFCE approach. Habitat International. 151. 103153–103153. 4 indexed citations

Yu, Lu‐Gang, Dezhi Li, Ling Mao, Shenghua Zhou, & Haibo Feng. (2023). Towards people-centric smart cities: A comparative evaluation of citizens’ sense of gain in pilot cities in China. Journal of Cleaner Production. 434. 140027–140027. 13 indexed citations

Herrmann, Anne, et al.. (2023). C1GalT1 expression reciprocally controls tumour cell-cell and tumour-macrophage interactions mediated by galectin-3 and MGL with double impact on cancer development and progression. Cell Death and Disease. 14(8). 547–547. 10 indexed citations

Duckworth, Carrie A., et al.. (2022). Galectin-2 in Health and Diseases. International Journal of Molecular Sciences. 24(1). 341–341. 16 indexed citations

Wu, Lei, et al.. (2022). Relationship between Gestational Weight Gain Rate Trajectory and Overweight in Offspring at Three Years of Age. Childhood Obesity. 18(8). 540–547. 2 indexed citations

Yu, Lu‐Gang, et al.. (2018). The clinical application study of platelet to lymphocyte ratio in type 2 diabetes-induced renal impairment in elderly patients. Zhonghua laonian yixue zazhi. 37(8). 883–887. 1 indexed citations

Zhang, Yahan, et al.. (2014). Preliminary Research on the Expression, Purification and Function of the Apoptotic Fusion Protein, Sival. Asian Pacific Journal of Cancer Prevention. 15(20). 8685–8688. 4 indexed citations

Chen, Chen, Carrie A. Duckworth, Qicheng Zhao, et al.. (2013). Increased Circulation of Galectin-3 in Cancer Induces Secretion of Metastasis-Promoting Cytokines from Blood Vascular Endothelium. Clinical Cancer Research. 19(7). 1693–1704. 87 indexed citations

10.

Yu, Lu‐Gang. (2013). Effects of isorhapontigenin on cell cycle arrest and down-regulation of cyclin D1 expression in bladder cancer cells. Zhongguo bingli shengli zazhi. 1 indexed citations

11.

Chen, Jinhua, et al.. (2012). 6r, a novel oxadiazole analogue of ethacrynic acid, exhibits antitumor activity both in vitro and in vivo by induction of cell apoptosis and S-phase arrest. Biomedicine & Pharmacotherapy. 67(1). 58–65. 12 indexed citations

12.

Barrow, Hannah, Xiuli Guo, Hans H. Wandall, et al.. (2011). Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium. Clinical Cancer Research. 17(22). 7035–7046. 139 indexed citations

13.

Zhao, Qicheng, Xiuli Guo, Gerard B. Nash, et al.. (2009). Circulating Galectin-3 Promotes Metastasis by Modifying MUC1 Localization on Cancer Cell Surface. Cancer Research. 69(17). 6799–6806. 138 indexed citations

14.

Yu, Lu‐Gang. (2009). Clinical Study on Parkinson's Disease Treated with "Xifeng Zhichan Decoction" and Madopar. Shanghai Journal of Traditional Chinese Medicine. 1 indexed citations

15.

Yu, Lu‐Gang, Qicheng Zhao, Oleg V. Gerasimenko, et al.. (2006). Galectin-3 Interaction with Thomsen-Friedenreich Disaccharide on Cancer-associated MUC1 Causes Increased Cancer Cell Endothelial Adhesion. Journal of Biological Chemistry. 282(1). 773–781. 248 indexed citations

16.

Yu, Lu‐Gang, et al.. (2004). Protein Phosphatase 2A, a Negative Regulator of the ERK Signaling Pathway, Is Activated by Tyrosine Phosphorylation of Putative HLA Class II-associated Protein I (PHAPI)/pp32 in Response to the Antiproliferative Lectin, Jacalin. Journal of Biological Chemistry. 279(40). 41377–41383. 62 indexed citations

17.

Yu, Lu‐Gang, Oleg V. Gerasimenko, Barry J. Campbell, et al.. (2002). An N-terminal Truncated Form of Orp150 Is a Cytoplasmic Ligand for the Anti-proliferative Mushroom Agaricus bisporusLectin and Is Required for Nuclear Localization Sequence-dependent Nuclear Protein Import. Journal of Biological Chemistry. 277(27). 24538–24545. 25 indexed citations

18.

Yu, Lu‐Gang, et al.. (2001). Opposite effects on human colon cancer cell proliferation of two dietary Thomsen-Friedenreich antigen-binding lectins. Journal of Cellular Physiology. 186(2). 282–287. 67 indexed citations

19.

Campbell, Barry J., Lu‐Gang Yu, & Jonathan M. Rhodes. (2001). Altered glycosylation in inflammatory bowel disease: A possible role in cancer development. Glycoconjugate Journal. 18(11-12). 851–858. 99 indexed citations

20.

Dwarakanath, A D, et al.. (1995). 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis.. Gut. 37(4). 585–588. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact